
















httpIncreasing efficacy of endovascular recanalization
with covered stent graft for TransAtlantic
Inter-Society Consensus II D aortoiliac complex
occlusion
Daniele Psacharopulo, MD,a Emanuele Ferrero, MD,a Michelangelo Ferri, MD,a Andrea Viazzo, MD,a
Sandeep Singh Bahia, MBBS,b Andrea Trucco, MD,a Fulvio Ricceri, MD,c and Franco Nessi, MD,a Turin,
Italy; and London, United KingdomObjective: We compared the outcomes and the durability of endovascular recanalization (EVR) with the Viabahn
(W. L. Gore and Associates, Flagstaff, Ariz) covered stent graft vs traditional aortobifemoral or aortofemoral bypass
grafting for complex aortoiliac occlusions.
Methods: Between 2008 and 2014, 11 unilateral iliac occlusions and 11 aortobiiliac occlusions were treated by EVR. Also
collected were data from the last 21 consecutive patients treated in the same period by aortofemoral (n [ 6) or
aortobifemoral (n [ 15) bypass grafting. In accordance with the TransAtlantic Inter-Society Consensus II (TASC II)
document, only patients with type D lesions were considered. Kaplan-Meier estimates for patency were calculated, and
Cox proportional hazard modeling was performed.
Results: The difference in risk factors between the groups was not significant. General anesthesia was required in 100% of
the surgical group, and local or locoregional anesthesia was used for EVR. Suprarenal aortic cross-clamping was required
in nine of the open surgical procedures (41%). A brachial percutaneous approach was performed in all patients undergoing
EVR, and technical success was 100% in both groups. All of the attempts at EVR were successful. At the 2-year follow-up,
primary patency did not differ significantly between the endovascular (91%) and surgical (95%) groups. This was seen in
the univariate model (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.02-2.95; P [ .28) and in the multivariate
model (HR, 0.77; 95% CI, 0.06-10.07; P[ .84) for group (HR, 0.58; 95% CI, 0.04-7.72; P[ .68), age (HR, 0.89; 95%
CI, 0.73-1.08; P [ .24), symptoms (HR, 1.98; 95% CI, 0.42-9.46; P [ .39), and occlusion (HR, 3.22; 95% CI,
0.51-20.35; P [ .21). The average hospital length of stay was shorter for patients treated with ERV than for those
treated with open surgery (3.9 6 2.2 vs 5.8 6 3.1 days, respectively; P [ .03). The complication rate was 4% for EVR vs
18% in the surgical group (P [ .32).
Conclusions: At 2 years of follow-up, the results of endoluminal bypass grafting with the Viabahn stent to treat complex
aortoiliac disease are promising. Longer-term results are needed to fully evaluate the potential benefits and longer-term
patency. (J Vasc Surg 2015;62:1219-26.)The TransAtlantic Inter-Society Consensus for the
Management of Peripheral Arterial Disease (TASC II)
consensus document classifies bilateral and unilateral iliac
occlusions as D lesions, with open surgical repair (OSR)
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treatment for aortoiliac complex occlusions, with a pri-
mary patency rate of >90% after 5 years. However,
ABF carries significant mortality (3.3%) and morbidity
(8.3%); therefore, high-risk patients are not always candi-
dates for what remains major surgery.2 Extra-anatomic
bypass grafting (axillofemoral bypass) is a potential alter-
native treatment for high-risk patients; however, longer-
term patency is poorer, with a primary patency rate of
63% after 5 years.3
With the advent of endovascular therapy, several
different techniques with a number of suitable devices are
reported for the treatment of this complex pathology.4-7
Endovascular recanalization (EVR) using the Viabahn
covered stent graft (W. L. Gore and Associates, Flagstaff,
Ariz) has been reported in some series but has never
been the subject of a focused study.6,8,9 The results of
this device in aortoiliac segment have never been compared
with the surgical standard treatment for this pathology.
Thus, the aim of this study was to evaluate our experience1219
Fig 1. A, Endoluminal recanalization from the brachial access with a 0.018-inch guidewire (arrow). In this case, an
occluded stent was crossed in the left iliac artery. B, The guidewire that comes from the brachial access has crossed the
occluded aortoiliac segment and is recovered into a 6F introducer sheet (arrow) positioned in the common femoral
artery. C, The guidewire (arrow) is directly recovered through the femoral artery exposure while endarterectomy with
profundoplasty is performed. D, Distal edge of a Viabahn (W. L. Gore and Assoc, Flagstaff, Ariz) stent graft (arrow)
positioned in the proximal segment of the femoral artery, crossing the inguinal ligament.
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occlusions compared with OSR.
METHODS
Patient selection criteria. Between January 2008 and
December 2014, 658 procedures for aortoiliac occlusive
disease were performed in our center. Forty-three pa-
tients were treated for abdominal aorta or iliofemoral
chronic total occlusion (CTO). Aortoiliac CTO is defined
as a proximal or distal aortic occlusion, or both, in addition
to unilateral or bilateral iliac occlusion. Iliofemoral CTO is
defined as a unilateral common and external iliac occlusion.
Data relating to these interventions were obtained from
our dedicated database, consisting of demographic data,
preoperative risk factors, clinical and diagnostic assess-
ments, symptoms at presentation (Rutherford scale),intraoperative features, and early and middle-term follow-
up results.10
Patients were grouped according to treatmentwithOSR
or EVR. The EVR group also included patients undergoing
hybrid repair. Hybrid repairs consisted of an endovascular
intervention as well as surgical exposure of the femoral ar-
teries with common or profunda femoris endarterectomy,
or both. The treatment decision was made by the referral
physician, after multidisciplinary team discussion.
The caseload in this study consisted of 18 patients pre-
senting with proximal aortoiliac occlusions (juxtarenal or
infrarenal), 8 with distal aortoiliac occlusions (below the
origin of the inferior mesenteric artery or intramesenteric),
and 17 with unilateral iliac occlusions. We also included pa-
tients with CTO involving the common femoral artery.
Aortic or iliac artery stenoses, without total occlusion,
Fig 2. A, Proximal edge of two Viabahn (W. L. Gore and Assoc, Flagstaff, Ariz) covered stents (arrow) positioned
immediately inferior to the renal arteries.B,Completion angiography after endovascular recanalization (EVR).C,A three-
dimensional computed tomography scan reconstruction after 6 months from the procedure shows a good result of the
procedure. D, Computed tomography image shows the proximal position of the two Viabahn covered stents (arrow).
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often treated with a bare-metal stent, hence the exclusion
of these lesions. Also excluded were patients who under-
went thrombolysis at any stage.
All patients who met the study criteria gave written
informed consent to undergo the proposed treatment,
and the protocol was locally approved from an ethics
perspective after review by a nominated committee.
Preoperative study. All patients underwent preopera-
tive diagnostic imaging with digital subtraction angiog-
raphy or computed tomography scan in addition to
duplex ultrasound imaging. All preoperative imaging was
reviewed to confirm the diagnosis, and patency of the
femoropopliteal and tibial vessels was evaluated. Patients
with stenosis or occlusion of the common femoral or pro-
funda femoral artery, or both, were eligible for a hybrid
procedure. After the primary intervention, patients were
considered to have “poor outflow” if they had occlusions
of one or both of their superficial femoral arteries.
Treatment techniques. OSR consisted of a conven-
tional aortobifemoral Dacron (DuPont, Wilmington, Del)
bypass grafting for aortoiliac CTO and aortofemoral dis-
ease and iliofemoral Dacron bypass grafting for unilateral
iliac CTO. Endovascular treatment consisted of EVR
with the Viabahn for aortoiliac or unilateral iliac CTO.
EVR technique. The EVR procedures were
performed in a hybrid operating theater using an Artis
Zeego system (Siemens AG, Forchheim, Germany) under
local or epidural anesthesia. Percutaneous brachial accesswas performed with a 6F hydrophilic introducer sheath.
Brachial arterial puncture was routinely performed 1 to
2 cm above the antecubital crease. Percutaneous femoral
access was obtained with a 6F hydrophilic introducer
sheath. When the occlusion also involved the common
femoral artery, surgical exposure of the common femoral
artery was performed and a hybrid procedure performed.
The occluded aortoiliac segments were crossed with a
0.018-inch guidewire by a brachial approach. Guidewire
position was determined to be transluminal or subintimal,
and then a 0.018-inch guidewire was recovered through
a femoral introducer or through the femoral artery surgical
exposure (Fig 1). Marked pigtail catheters were routinely
used to ensure correct selection of endograft length.
Appropriate Viabahn diameter was selected based on
preoperative digital subtraction angiography images using
the diameter of an arterial segment on the ipsilateral side.
For unilateral occlusions, the contralateral side was used
for diameter evaluation and selection. For aortoiliac
CTO, the standard diameter was 8 mm proximal (in the
aorta) and 7 mm in the distal iliac artery. Viabahn stent
grafts were deployed simultaneously via the femoral access
to cover the entire arterial occlusion (Fig 2).
For juxtarenal occlusions, the proximal edge of the Via-
bahn stent graft was positioned immediately inferior to the
renal arteries. If the occlusion involved the common femoral
artery, the distal edge of the Viabahn stent graft was posi-
tioned near the proximal segment of the femoral artery,
crossing the inguinal ligament. In all cases the Viabahn stent
Table I. Preoperative demographic variables for patients
undergoing endovascular and hybrid recanalization
(EVR) or open surgical repair (OSR) with aortobifemoral






(n ¼ 21) P value
Age, mean 6 SD years 64.2 6 8.1 67 6 6.4 .27
Gender, No.
Male 15 15 .40
Female 7 6 .40
Hypertension, No. 19 19 .99
Diabetes, No. 8 2 .07
Coronary artery disease, No. 5 2 .41
Renal failure,a No. 1 2 .96
Hyperlipidemia,b No. 12 7 .16
Smoking, No. 15 18 .17
Rutherford stage, No.
III 13 15 .29
IV 7 5 .40
V 2 1 .29
Occlusion, No.
Proximal aortoiliac 7 11 .14




Poor out flow (SFA occlusion) 8 9 .66
SD, Standard deviation; SFA, superficial femoral artery.
aDefined as patients with elevated serum creatinine concentration
>1.5 mg/dL.
bDefined as patients with elevated plasma lipids or under medical treatment.
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success of the EVR was defined as successfully crossing the
occlusion and correctly deploying the stent graft, with no
measurable hemodynamic pressure gradient across the lesion.
All patients received unfractionated heparin (50 U/kg)
during the procedure and were discharged with dual-
antiplatelet therapy (aspirin, 100 mg; clopidogrel, 75 mg)
and a statin.
OSR technique. All ABFs were performed under gen-
eral anesthesia via a conventional transperitoneal approach.
A suprarenal cross-clamp was performed for juxtarenal
occlusions. In all cases, a Dacron bifurcated graft was used
to perform end-to-side proximal and distal anastomoses.
For unilateral iliac occlusions, the site of proximal cross-
clamping was the distal aorta or the proximal common
iliac artery. An end-to-end proximal anastomosis was used,
with an end-to-side distal anastomosis. Technical success of
OSR was defined as successful bypass of the occluded
segment with a prosthetic graft in the absence of graft
thrombosis.
All patients received unfractionated heparin (50 U/Kg)
during the intervention and were discharged on single-
antiplatelet therapy and a statin.
Follow-up. All patients underwent duplex ultrasound
scans 6 months after the procedure and then every
12 months. The median length of follow-up was
28 months. Primary and secondary patency rates were
determined according to the Society for Vascular Surgeryguidelines.10 Loss of patency and other complications were
determined by duplex ultrasound imaging and confirmed
with formal angiography.
Statistical analysis. Data are presented as frequency
and percentage for qualitative variables and means and
standard deviation for quantitative variables. Baseline com-
parisons for qualitative variables were conducted using c2
and Fisher exact tests. Baseline comparisons for quantitative
variables were conducted using the Wilcoxon sum rank test.
Patency was analyzed with univariate and multivariate Cox
proportional hazard models adjusted for age, symptoms,
and type of occlusion. Analyses were performed using SAS
9.3 (SAS Institute Inc, Cary, NC) and Stata 10.1 (StataCorp
LP, College Station Tex) software. All tests were two-tailed,
and an overall P ¼ .05 was considered significant.
RESULTS
Of the 43 patients who met the inclusion criteria for
the study, 22 were treated by EVR and 21 by OSR. All pa-
tients had TASC II D lesions, and the two groups had
similar risk factors, symptoms at presentation, runoff status,
and level of arterial occlusion, as reported in Table I.
EVR group. The 22 patients in the EVR group under-
went 14 endovascular procedures and eight hybrid proce-
dures. Local anesthesia was used in 10 procedures and
locoregional anesthesia in 12. Technical success was
achieved in all cases. Four patients required a subintimal
recanalization, and the recanalization for the remaining
18 patients was performed via an endoluminal approach.
Endarterectomy with profundoplasty was performed in
36% (8 of 22) of ERV patients. No stent compression or
fracture was seen, including cases crossing the inguinal lig-
ament, and there were no instances of distal artery emboli-
zation. No patients in this group required concomitant
lower extremity bypass. Manual compression was used for
hemostasis, although conversion to surgical closure was
performed in one patient.
No patient experienced nerve sheath hematoma, brachial
occlusion, hematoma, arm ischemia, or stroke. Acute renal
failure (serum creatinine >2 mg/dL) developed in two pa-
tients in the EVR group, with spontaneous resolution. No
patient experienced renal or visceral artery embolization.
At 2 years of follow-up, cumulative primary for the
EVR group was 94% (31 of 33 limbs) and secondary
patency was 97% (32 of 33 limbs). Two unilateral occlu-
sions occurred in patients who underwent aortoiliac bilat-
eral EVR recanalization with a purely endovascular
procedure. The first occurred at 19 months with critical
limb ischemia and was treated with thrombolysis and distal
external iliac artery relining with a Viabahn stent. The
occlusion was deemed to be due to external iliac artery
tortuosity just below the distal edge of the Viabahn. The
second patient had a unilateral occlusion at a similar time
with mild to moderate claudication. The patient chose con-
servative management given his mild symptoms and after
discussion of the treatment options.
OSR group. All surgical procedures were performed
under general anesthesia. Technical success was achieved
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cross-clamping. Transitory renal failure (serum creatinine
>2 mg/dL) developed in two patients, with spontaneous
resolution. Nine of the 21 surgical repairs (43%) were
associated with endarterectomy and profundoplasty
(3 unilateral and 6 bilateral).
The 2-year primary patency rate for the OSR group
was 97% (35 of 36 limbs) and secondary patency was
100% (36 of 36 limbs). One unilateral and one bilateral oc-
clusion occurred after 19 and 33 months. The first
(19 months) was due to poor runoff and treated with
thrombectomy and femoropopliteal jump bypass grafting.
The second patient (33 months) presented with moderate
claudication and was managed conservatively. There were
four major complications in this group: 1 patient had pneu-
monia on the second postoperative day, 2 patients with
double-antiplatelet therapy for a recent percutaneous trans-
luminal coronary angioplasty underwent surgical revision
for hemoperitoneum (on the third and fifth postoperative
days, respectively), and 1 patient underwent surgical revi-
sion after 18 months for an incisional hernia.
Group comparison. Median follow-up time was 28 6
21.5 months (range, 5-112 months) for the entire cohort.
Primary occlusion rate was 0.58/100 person-years in the
EVR group and 0.31 in the OSR group. No significant
difference was found between primary patency by limb at
2 years (94% [33 of 31 limbs) in the EVR group vs 97% [35
of 36 limbs]) in the OSR group (P ¼ .50). At the 2-year
follow-up, the difference in overall primary patency be-
tween the EVR and OSR group was not significant in the
univariate model (hazard ratio [HR], 0.27; 95% confidence
interval [CI], 0.02-2.95; P ¼ .28; Fig 3) and the multi-
variate model (HR, 0.77; 95% CI, 0.06-10.07; P ¼ .84). A
multivariate analysis to test the possible effects of other
variables, such as group (HR, 0.58; 95% CI, 0.04-7.72;
P ¼ .68), age (HR, 0.89; 95% CI, 0.73-1.08; P ¼ .24),
symptom (HR, 1.98; 95% CI, 0.42-9.46; P ¼ .39), and
occlusion (HR, 3.22; 95% CI, 0.51-20.35; P ¼ .21) found
no significant differences between the groups.
The average hospital length of stay was shorter for pa-
tients treated with EVR (3.9 6 2.2 days) vs OSR (5.8 6
3.1 days; P ¼ .03). The complication rate was 4% for
ERV vs 18% for OSR (P ¼ .32).
DISCUSSION
Endovascular treatment with bare-metal stents for aor-
toiliac disease in TASC II A and B lesions has demonstrated
excellent results, with 1-year primary patency of 95%.11
Recent studies are currently extending the endovascular
treatment recommendations for TASC II C and D lesions,
traditionally the preserve of OSR.5,6,12
However, despite the technologic improvement of the
devices, there is a relative paucity of endovascular devices
specifically designed for aortoiliac occlusive diseases.
Bare-metal stents, balloon-expandable stents, and self-
expandable covered stents and endografts have been used
for the treatment of this pathology.4-9 The self-expanding
Viabahn covered stent graft is the only device approvedby the U.S. Food and Drug Administration for use in iliac
arteries, but not in the distal or proximal aorta. The Advanta
V12 (AtriumMedical Corp, Hudson, NH) is also approved
for iliac artery occlusive disease, but in Europe only.
Covered stents that have been approved for other indica-
tions are used off label for treating aortoiliac diseases.
Bare-metal stents. Early reports of recanalization of
this pathology report angioplasty and bare-metal stenting
as the most commonly used technique to treat iliac stenosis
and occlusion.13 Some studies have advocated the advan-
tage of primary stenting over percutaneous transluminal
angioplasty alone for the treatment of iliac artery occlu-
sion.6-14 Patients with occlusive lesions of the proximal
common iliac artery represent a complex subgroup, and the
results associated with the use of iliac artery kissing bare-
metal stents have been less encouraging when the stents
extend into the aorta.7 This is most likely caused by the
hemodynamic effect or lack of neoendothelialization of the
free end of the bare stents within the aortic lumen, which
could increase thrombogenicity. Moreover, iliac arterial
rupture after angioplasty and bare-metal stent placement is
a potential risk of the procedure.14
Covered stents. Some studies suggest the use of
covered balloon-expandable stents confer the advantage
of decreased thrombogenicity, with less chance of plaque
prolapse through a covered stent and less ingrowth of hy-
perplastic tissue compared with bare-metal stents.7-9
In general, most studies focusing on the use of covered
stents in iliac artery occlusion report superiority over
uncovered stents.7 Conversely, recent studies claim the su-
periority of bare-metal stents compared with covered
balloon-expandable stents for treatment of aortoiliac occlu-
sive disease. Humphries et al15 recently reported their expe-
riences of recanalizing occluded iliac arteries treated by
bare-metal stent vs covered stent and concluded that primary
patencywas significantly better in the bare-metal stent group
(89% 6 3% vs 72% 6 6%; P ¼ .008).15 The debate is there-
fore still open, and this is reflected by ongoing trials.16
Stent grafts (component of endoprosthesis). Some
studies have demonstrated the efficacy of using stent grafts
for aortoiliac occlusive disease.17 Zander et al9 used a
bifurcated aortic endovascular prosthesis in 14 patients,
and reported a primary of 85.7% and secondary patency of
100% at a mean follow-up of 62 months. However, the use
of stent grafts for aortic bifurcation occlusive disease re-
quires large introducer sheath sizes in the face of potentially
small access vessels and has higher associated treatment
costs. Moreover, a decreased diameter of the aorta or iliac
arteries makes the procedure technically challenging and
carries the inevitable potential risk of graft occlusion.18
Other techniques have been described, such as covered
endovascular reconstruction of the aortic bifurcation
(CERAB). This technique describes the use of an aortic
cuff that covers the proximal edge of the iliac covered stents
in the distal aorta in an attempt to reconstruct the aortic
bifurcation in a more anatomic fashion.19 A recent study
by Jebbink et al20 analyzed, in vitro, the geometric conse-
quences of CERAB compared with three alternatives:
Fig 3. Kaplan-Meier and 95% confidence interval (CI) curve estimates for primary patency in patients undergoing
endovascular recanalization (EVR) with a Viabahn (W. L. Gore and Assoc, Flagstaff, Ariz) covered stent vs an open
surgical procedure (OSR). No significant difference was found between the EVR and OSR groups at 24 months
(hazard ratio [HR], 0.27; 95% CI, 0.02-2.95; P ¼ .28).
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covered stent, and another variant of the CERAB tech-
nique. They reported that the CERAB configuration with
the iliac legs positioned inside the tapered part of the aortic
cuff has the lowest radial mismatch, which can minimize
flow perturbations and thrombus formation. However,
this remains an in vitro model and may not correlate to clin-
ical outcome.
Viabahn covered stent. No previous study has
focused solely on the use of Viabahn covered stents for aor-
toiliac CTO. Lammer et al,21 in 2000, reported the results
of the Hemobahn covered stent graft (W. L. Gore and
Associates), but they included also iliac artery stenotic le-
sions, with a reported primary patency rate of 91% at
12 months. Other studies have reported experiences with
the Viabahn device, but they usually analyzed its results in
combination with other covered stents and typically also
considered patients with TASC II B lesions (Table II).
We exclusively used the Viabahn covered stent, without
an aortic cuff, to perform our EVRs. In our opinion, the Via-
bahn has three main advantages: (1) it is a covered stent,
providing a direct barrier to the ingrowth of neointimal hy-
perplasia; (2) it is extremely flexible, minimizing the risk of
occlusion due to kinking in the tortuous external iliac artery;
and (3) it is low profile, allowing the 7-mm and 8-mmdevices to be deployed via a 7F introducer sheath. In
2008, the Gore Viabahn received U.S. Food and Drug
Administration indication for use in the treatment of iliac
occlusive disease, although our use of these stents with
extension in the aortic bifurcation is still out of the instruc-
tion for use.24
In our study, mean infrarenal aortic diameter was
18.8 6 3.1 mm. No proximal stent compression was
recorded in any patient. We can postulate that a proximal
aortic diameter of <14 mm might increase the chances of
stent compression. In this case, choosing a proximal stent
diameter of 7 mm would probably be better.
Our results show no significant difference related to
patency between OSR and EVR with the Viabahn covered
stent. We reached a 100% technical success rate mainly
thanks to the brachial access, which leads us to cross the
occluded arterial tract in all cases, and also thanks to the
high conformability of the endograft. Thanks to the endog-
raft low profile, we did not have any access vessel injury. The
fact that the Viabahn is a covered stent mitigates some of
the potential risk of vessel rupture during the course of
recanalization.
For patients with a juxtarenal occlusion, the only
complication was an episode of acute renal failure in the
EVR group. Notably, we also observed acute renal failure
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TASC II, TransAtlantic Inter-Society Consensus.
All these studies report treatment of TASC C and D and some of them even TASC B lesions. The covered stents considered are Viabahn and Hemobahn (W.
L. Gore and Assoc, Flagstaff, Ariz), Advanta-V12 and Icast (Atrium Medical Corp, Hudson, NH), Fluency (Bard, Lowell, Mass), Wallgraft (Boston Scientific,
Natick, Mass), Cordis polytetrafluoroethylene-covered nitinol stents (Johnson & Johnson, Waterloo, Belgium).
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resolved spontaneously after appropriate management,
with no evidence of renal artery occlusion or embolism.
When the distance between the lowest renal artery and
the aortic occlusion is <2 cm, some authors suggest the use
of renal protection devices such as guidewires, filters, or
balloons.25 In our experience, seven of the described cases
had proximal aortic occlusions, and our patients experi-
enced no complications despite not using a renal protection
device. A possible explanation for this is that all of our re-
canalizations were done via a brachial approach, although
one must bear in mind that renal embolization can also
occur during predilatation and deployment of the endog-
raft. The limited numbers in this series make it difficult
to draw a meaningful conclusion on this.
In terms of runoff vessels, common femoral artery
occlusion was quite common among these patients. We per-
formed femoral endarterectomy in almost one-third of the
cases in both groups, which reflects the advanced level of dis-
ease; however, this had no significant effect on the patency of
the endografts. Although at potential risk of stent compres-
sion or fracture, covered stenting crossing the inguinal
ligament was safe and effective in this series, as reported by
other series.26 Patients with superficial femoral artery occlu-
sion, even if affected by Rutherford 4 lesions, did not un-
dergo concomitant lower limb bypass or revascularization.
We adopted a policy of performing aortoiliac recanalization
first to see if the restored inflow was sufficient.
For OSR, although aortounifemoral bypasses have
been reported to have poorer outcomes than aortobife-
moral grafting, we did not observe this phenomenon. At2 years, the only limb occlusion recorded occurred in a
patient treated with an ABF graft.
Study limitations. This study is limited by the small
sample size, the lack of prospective randomization, and
by the relatively short follow-up. However, we believe
the comparison is still a valid one.
CONCLUSIONS
EVR with the Viabahn stent graft for complex aortoil-
iac occlusion is a safe and effective treatment, which seems
a valid alternative to OSR for its comparable outcome at
2 years. A prospective trial with longer follow-up might
be able to clarify if these encouraging results will be result
in similarly promising long-term outcomes.
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